Francesca CONRADIE to Cost-Benefit Analysis
This is a "connection" page, showing publications Francesca CONRADIE has written about Cost-Benefit Analysis.
Connection Strength
0,352
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
Score: 0,207
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
Score: 0,050
-
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021 12 03; 11(12):e051521.
Score: 0,042
-
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
Score: 0,032
-
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011 Feb 20; 25(4):479-92.
Score: 0,020